vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Last trade$17.51
Day change-$0.18 (-1.02%)
Day range$16.48 – $17.84
Volume24,116
Market cap$71M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$70.96M
Price / earnings
—
Price / book
1.02×
Price / sales
1.93×
EV / sales
-0.17×
EV / EBITDA
0.56×
Profitability
Earnings per share
-$1.91
Return on assets
-9.77%
Return on equity
-11.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.19×
Quick ratio
11.19×
Cash ratio
10.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.73M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VTVT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$36.84M
$0
$0
$0
$0
$17K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$36.84M
$0
$0
$0
$0
$17K
Selling, general and administrative
$4.9M
$5.16M
$4.6M
$3.98M
$3.68M
$3.62M
$3.67M
$2.68M
Research and development
$7.53M
$8.77M
$8.98M
$3.91M
$7.02M
$4.1M
$2.83M
$2.23M
Total operating expenses
$12.43M
$13.93M
$13.58M
$8.02M
$10.7M
$7.72M
$6.5M
$4.9M
Operating income
-$12.43M
-$13.93M
$23.26M
-$8.02M
-$10.7M
-$7.72M
-$6.5M
-$4.88M
Interest expense
$0
$0
$0
-$1K
-$5K
$0
$0
$0
Income before taxes
-$11.62M
-$13.05M
$24.13M
-$7.14M
-$10.35M
-$7.38M
-$6.22M
-$4.44M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$11.62M
-$13.05M
$24.13M
-$7.14M
-$10.35M
-$7.38M
-$6.22M
-$4.44M
Net income attributable to common shareholders
-$11.62M
-$13.05M
$24.13M
-$7.14M
-$8.7M
-$6.05M
-$5.09M
-$3.63M
EBITDA
-$12.43M
-$13.93M
$23.26M
-$8.02M
-$10.7M
-$7.72M
-$6.49M
-$4.86M
Basic earnings per share
-$0.94
-$1.05
$1.94
-$0.57
-$1.08
-$0.92
-$0.77
-$0.51
Diluted earnings per share
-$0.94
-$1.05
$1.65
-$0.57
-$1.08
-$0.92
-$0.77
-$0.51
Recent news
Company coverage with links to the original publishers.
iOnctura, a clinical-stage precision oncology company, announced the appointment of Paul Sekhri as Chair of its Board of Directors. Sekhri brings over 35 years of life science executive experience and has led multiple biotech companies through commercialization. The appointment comes as iOnctura prepares for late-stage development of roginolisib, its lead PI3Kδ inhibitor candidate, with two randomized Phase II studies fully enrolled. Roginolisib has shown promising clinical signals including doubled overall survival in uveal melanoma compared to historical controls.
vTv Therapeutics announced that management will participate in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference on September 16 and the 5th Annual ROTH Healthcare Opportunities Conference on September 29. The company continues advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes, with its Phase 3 CATT1 trial expected to complete enrollment in Q3 2026.
vTv Therapeutics appointed a Scientific Advisory Board of distinguished clinicians and scientists to provide strategic guidance on cadisegliatin, a potential oral treatment for type 1 diabetes currently in Phase 3 clinical trials.
vTv Therapeutics received a USPTO patent for crystalline forms of cadisegliatin, a potential oral treatment for Type 1 diabetes, with patent protection extending through 2041.
vTv Therapeutics has appointed Michael Tung as its new Chief Financial Officer. The company has also reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.